Anchiano Therapeutics Appoints Efrat Makov to its Board of Directors
August 30, 2018 08:30 ET
|
Anchiano Therapeutics
Former CFO of Alvarion brings decades of experience to Board CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company...
BioCanCell Announces Company Name Change to Anchiano Therapeutics
August 27, 2018 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat...
BioCanCell Reports Second Quarter 2018 Financial and Operational Results
August 22, 2018 08:30 ET
|
BioCanCell, Ltd.
CAMBRIDGE, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat...
BioCanCell Announces Completion of $23 Million PIPE Financing
July 03, 2018 08:30 ET
|
BioCanCell, Ltd.
CAMBRIDGE, Mass., July 03, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
BioCanCell Reports First Quarter 2018 Financial and Operational Results and Provides Corporate Update
May 15, 2018 08:00 ET
|
BioCanCell, Ltd.
Presented final data from its Phase 2 study of BC-819 for early stage bladder cancer at the 2018 ASCO Genitourinary Cancers Symposium Announced two key hires in clinical development and clinical...
BioCanCell Announces $23 Million PIPE Financing
April 13, 2018 08:00 ET
|
BioCanCell, Ltd.
Financing, led by Shavit Capital, includes U.S. and Israeli investors CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company...
BioCanCell Announces Two New Key Hires in Clinical Development and Clinical Operations
March 07, 2018 08:00 ET
|
BioCanCell, Ltd.
Ronald Knickerbocker, Ph.D. named Senior Vice President of Clinical Development and Data Sciences Sean Daly named Vice President of Clinical Operations CAMBRIDGE, Mass., March 07, 2018 (GLOBE...
BioCanCell Presents Final Data from Its Phase 2 Study of BC-819 for Early Stage Bladder Cancer at the 2018 ASCO Genitourinary Cancers Symposium
February 09, 2018 15:15 ET
|
BioCanCell, Ltd.
BC-819 demonstrates meaningful activity Two registrational studies planned to be initiated in 2018 CAMBRIDGE, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a...